This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Senior Vice President, Global Chief Medical Officer, Global Medical Affairs, Novo Nordisk A/S, Copenhagen, Denmark

Stephen Gough joined Novo Nordisk A/S in Copenhagen, Denmark as Senior Principal Clinical Scientist in 2015 in the Chief Medical Office, to provide advice and clinical guidance on the development of new molecules and drugs, from early through to phase 3 and beyond, for the treatment of diabetes and obesity. In 2018, he became Senior Vice President and Global Chief Medical Officer, and in 2021 also became responsible for Global Medical Affairs.


Prior to joining Novo Nordisk, Stephen was Head of the Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM), Oxford, UK and served as Professor of Diabetes to the University of Oxford and Consultant Physician at the Oxford University of Hospitals NHS Trust. He was also the Diabetes Clinical Lead for the Local Clinical Research Network and the Academic Health Science Network in Oxford.


Stephen’s research interests have resided in the fields of the genetics of autoimmune disease, glucose homeostasis, incretin biology in pancreas whole organ and islet transplantation, and clinical trials of GLP-1-based therapies. Since joining Novo Nordisk, he has supported a number of activities and provided senior medical opinion in diabetes, obesity and biopharmaceuticals.


Rachel Batterham

Professor of Obesity, Diabetes and Endocrinology, University College London, London, UK

Professor Rachel Batterham is Professor of obesity, diabetes and endocrinology at University College London (UCL), London, UK. She leads the University College London Hospital (UCLH) Bariatric Centre for Weight Management and Metabolic Surgery and the UCL Centre for Obesity Research within the Department of Medicine. She is Clinical Director for the Division of Medicine at UCL, Director for the UCLH/UCL NIHR Biomedical Research Centre obesity research theme and Special Advisor on obesity for the Royal College of Physicians. 


In 2022, she was awarded Officer of the Order of the British Empire (OBE) by Queen Elizabeth II for her services to people affected by obesity. She has also received several national and international awards for her work in obesity, including the Royal Society of Medicine’s Stevens Lecture (2018), the Andre Mayer award from the World Obesity Federation (2016) and the Diabetes UK Rank Prize Funds Nutrition (2015).


Professor Batterham has made significant clinical contributions to defining the management of obese patients through her membership of the National Institute for Health and Care Excellence Guideline Development Group on obesity. She is co-chair of NHS England’s Clinical Advisory Group for specialist weight management, and since 2016, she has been a trustee for the Association for the Study of Obesity and Council Member for British Obesity and Metabolic Surgery Society. She is passionate about reducing the stigma that people with obesity experience and ensuring that the patient voice is heard. She has established a charity for people affected by obesity, the Obesity Empowerment Network UK.

Read full bio

Domenica Rubino

Washington Center for Weight Management and Research, Arlington, VA, USA

Dr Domenica Rubino is Founder and Director of the Washington Center for Weight Management and Research in Arlington, VA, USA, a comprehensive weight management programme utilising a multidisciplinary team for the care of individuals with obesity. Dr Rubino is board certified in obesity medicine, endocrinology, diabetes and metabolism, and internal medicine, and received training in both clinical and molecular biological research at the US National Institutes of Health. She is currently a clinical investigator for Epitomee, Boehringer Ingelheim and Novo Nordisk, and is the recipient of an independent research grant from Obesinov, SARL. She has over 20 years of experience in the care of individuals with obesity as well as in pharmacotherapeutic development for the treatment of obesity. 


She currently serves as a clinical expert on the treatment of obesity for several professional committees, and as a consultant and speaker for Novo Nordisk. She has also served as a representative to Congress and outside organisations for The Obesity Society. 


Dr Rubino has received several investigator awards and has published articles in peer-reviewed publications, including JAMA, Lancet, International Journal of Obesity, Postgraduate Medicine, Obesity, European Journal of Endocrinology, Journal of Clinical Endocrinology & Metabolism, and Diabetes, Obesity and Metabolism. She recently contributed a chapter on ‘Biopsychosocial modifiers of obesity’ for the textbook entitled Bariatric Endocrinology, published by Springer Verlag.

Read full bio

Ofri Mosenzon

Hebrew University of Jerusalem Medical School and School of Public Health, Jerusalem, Israel

Professor Ofri Mosenzon MD, MSc is Professor of Internal Medicine, Endocrinology and Epidemiology at the Hebrew University of Jerusalem Medical School and School of Public Health in Jerusalem, Israel.  


She is board certified in internal medicine and endocrinology. She is Director of the Diabetes Clinical Research Center, Diabetes Unit, Department of Endocrinology and Metabolism at Hadassah Hebrew University Hospital.  


Professor Mosenzon has been involved in more than 80 clinical trials related to diabetes, obesity, cardiovascular outcome trials (CVOTs), diabetic nephropathy and others. She is part of distinguished academic international groups leading large international CVOTs, including SAVOR-TIMI 53, DECLARE-TIMI 58 and PIONEER 6. She has published widely on a range of diabetes topics, including treatment of diabetes and cardiovascular and renal complications of diabetes. She has presented at many national and international conferences, including American Diabetes Association, Endocrine Society’s annual meeting, American Society of Nephrology, European Renal Association-European Dialysis and Transplant Association, and European Association for the Study of Diabetes Scientific Sessions. 


Professor Mosenzon is very involved in developing curriculums for continuing medical education for family physicians in diabetes and lecturing to medical and master’s students. She is Founder and Academic Director of the school of continuing medical education in the faculty of medicine at the Hebrew University of Jerusalem.


Professor Mosenzon has contributed chapters in books relating to diabetes treatment in Israel. She has many (and quickly growing numbers) of original papers, reviews, commentaries and editorials in leading peer-reviewed journals.  

Read full bio

Ildiko Lingvay

University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA

Dr Ildiko Lingvay is Professor of Medicine in the Division of Endocrinology as well as the Department of Population and Data Sciences at UT Southwestern Medical Center. Dr Lingvay is Medical Director of the Office of Clinical Trials Management, overseeing all clinical trials at UT Southwestern. She is board certified in obesity medicine as well as endocrinology, diabetes and metabolism.


Dr Lingvay leads a programme that focuses on clinical research in the field of obesity and type 2 diabetes, with the ultimate goal to improve the lives of all patients who suffer so many health consequences as a result of their medical problems. Her research interests span the spectrum from pathophysiology of the disease to treatment algorithms and comparative effectiveness of various therapeutic approaches. Dr Lingvay treats patients at the UT clinics and hospitals as well as the Parkland Health & Hospital System, Dallas, TX, USA. 


Dr Lingvay is an active member of the American Diabetes Association (ADA), where she has served over the years on several committees, including the organising committee for the annual scientific sessions, Focus on Fellows advisory board and Women’s Interprofessional Network ADA advisory board. She has participated in many clinical trials and has a special interest in cardiovascular outcome trials. She has authored over 110 publications in major medical journals and authored chapters in several popular diabetes textbooks.

Read full bio

Julia Mader

Medical University of Graz, Graz, Austria

Dr Julia Mader is Associate Professor of Medicine at the Division of Endocrinology and Diabetology at Medical University of Graz, Austria, and is Deputy Head of the Diabetes Outpatient Clinic. She received her medical degree at Medical University of Graz, where she also trained in internal medicine, and endocrinology and diabetology. From 2016 to 2017, she was Visiting Professor at the Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism at the University Hospital of Bern, Switzerland. She leads the Diabetes Technology Research Unit at Medical University of Graz.


Dr Mader’s research is focused on diabetes technology with emphasis on insulin pumps, continuous glucose monitoring, the artificial pancreas and decision support systems for the treatment of diabetes. She has published over 100 peer-reviewed scientific papers and serves as Associate Editor for Frontiers in Clinical Diabetes and Healthcare. She has received several national and international awards in the field of diabetes technology. In 2021, she was awarded with the Langerhans Award of the Austrian Diabetes Association. Dr Mader is a member of the European Association for the Study of Diabetes, the Austrian Society for Internal Medicine, the Austrian Diabetes Association and the Austrian Society for Endocrinology. She is also a management board member of the Austrian Diabetes Society, within which she heads the Diabetes Education Committee and is a member of the Diabetes Technology Committee. Dr Mader has authored and co-authored several national guidelines in the field. 

Read full bio

Klara Owen

Novo Nordisk A/S, Bagsværd, Denmark

Klara Owen is the senior medical director medically responsible for all projects in type 1 diabetes (T1D) at the Cell Therapy R&D Transformational Research Unit (TRU), Novo Nordisk A/S, Denmark. She holds an MD degree from the First Faculty of Medicine, Charles University, Prague, Czech Republic. Her PhD, from the same university, centred around the dynamic interplay between weight change and glycaemic and lipid metabolism. She is also board certified in internal medicine and diabetology, as well as holding an MSc in drug development science from King’s College, London, UK. 


After 12 years of both in- and outpatient practice in internal medicine and obesity/type 2 diabetes, for the last 5 years as Consultant Diabetologist, Klara joined Novo Nordisk A/S in Copenhagen, Denmark, to support treat-to-target diabetes clinical trials with design and surveillance of trial execution. She then moved to the newly formed obesity division, focusing on translation from research into clinical development for a number of novel obesity treatment compounds. Klara subsequently joined Zealand Pharma, supporting the development of short-acting glucagon analogue for a congenital hyperinsulinism indication and a dual hormone artificial pancreas collaboration with BetaBionics, Boston, MA, USA. 


Recently, Klara joined the cell therapy TRU to support the research and translational work of developing human embryonic stem cell-derived islet clusters for treatment, and potentially cure, of T1D. In addition to her work on the T1D projects, she supports the pre-project portfolio in a number of other indications, while continuing to be a passionate advocate of listening to patient perspectives to modify, change or re-prioritise development programmes.

Read full bio

Abd Tahrani

International Medical Vice President, Obesity & NASH, Clinical Drug Development Novo Nordisk, Søborg, Denmark

Abd Tahrani is currently International Medical Vice President, Obesity & NASH, Clinical Drug Development, Novo Nordisk in Søborg, Denmark. He is also an honorary senior lecturer in metabolic endocrinology and obesity medicine at the University of Birmingham and an honorary consultant in endocrinology, diabetes and weight management at the University Hospitals Birmingham NHS Foundation Trust.


Prior to joining Novo Nordisk in July 2021, Abd was the lead for translational research at the Centre of Endocrinology, Diabetes and Metabolism, Birmingham Health Partners; the chair of the clinical committee of the Association for the Study of Obesity UK; and the chair of the Type 2 Diabetes Research Steering Group for Diabetes UK. He also was a panel member of the Diabetes, Obesity, Metabolism and Nutrition Focus Area of the European Society for Endocrinology; the British Sleep Society Research Committee; the National Institute for Health and Care Research (NIHR) Research for Patient Benefit programme and NIHR Dissemination panels; the Obesity Policy Engagement Network UK; the clinical committee of the Society for Endocrinology; and the strategic council of the Obesity All Party Parliamentary Group. Abd also served as an expert advisor to National Institute for Health and Care Excellence technology appraisals in obesity and neuropathy. Abd held several editorial roles including the associate editor for the European Journal of Endocrinology and the senior editor for BMC Endocrine Disorders.


Abd received several awards, including NIHR Research Training Fellowship (2008), NIHR Clinician Scientist (2012), the American Academy of Sleep Medicine young investigator award in obstructive sleep apnoea research (2013), and SCOPE national and international fellowships from the World Obesity Federation (2014 and 2020), amongst others. Abd obtained more than £4 million in grants funding to support his research themes, which included: 1) the metabolic consequences of sleep-related disorders; 2) obesity management and healthcare delivery; and 3) diabetes-related neuropathy.


Abd has published over 180 peer-reviewed articles and delivered more than 110 invited talks in the leading conferences in diabetes, obesity, endocrinology and sleep globally.   

Read full bio

Gerard Kees Hovingh

Senior Medical Officer, Global Medical Affairs, Novo Nordisk A/S, Copenhagen, Denmark

Gerard Kees Hovingh has served as Senior Medical Officer, originally in the Global Chief Medical Office, and now Global Medical Affairs at Novo Nordisk in Copenhagen, Denmark since 2019. In this role, his responsibilities include defining and driving the R&D cardiovascular disease (CVD) strategy to address clinical needs for individuals living with obesity, CVD, diabetes and chronic kidney disease. He is involved in the evaluation of the clinical value of products and services at different stages of development, ranging from preclinical idea generation to leveraging the clinical value of marketed products. Kees is a member of a number of clinical trial steering committees, including ZEUS, SELECT, SOUL, Step-HF and the ATTR Phase 2 trial. 


Kees received his medical degree in 2000, his PhD in 2005 and his MBA degree in 2016 from the University of Groningen, the Netherlands. He is a full professor, internist and vascular medicine specialist at the Department of Vascular Medicine, University Medical Center Amsterdam (UMCA), the Netherlands. Kees was Co-chair of the department of internal medicine at UMCA in 2016–2019, and in his role as Head of the clinical trial unit (2012–2019), he has been involved in a large number of clinical trials, mainly focused on novel therapies to address dyslipidaemia, thrombosis and haemophilia. His research focuses on genetics and molecular biology in CVD, and he did a post-doctoral fellowship at Harvard Genetics in Boston, MA, USA. Kees co-authored over 300 publications (Scholar h-index: 91) and was named by Thomson Reuters in 2019 as the top 1% most cited researchers.

Read full bio